Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | LIG1 | P18858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22361964 | 0.91 | LIG1 (0.37) | CYP2A6ALDH1A1TAAR1OPRM1OPRD1 | |
| SCHEMBL20876288 | 0.77 | SLC6A3 (0.39) | OPRM1LIG1 | |
| SCHEMBL20876286 | 0.77 | SLC6A4 (0.40) | CYP2A6OPRM1 | |
| SCHEMBL4046273 | 0.77 | CYP2A6 (0.36) | CYP2A6TAAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL31219459 | 0.77 | CYP2A6 (0.36) | CYP2A6TAAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL498413 | 0.76 | OPRL1 (0.50) | TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL22361962 | 0.75 | ALDH1A1 (0.39) | ALDH1A1OPRM1OPRK1OPRL1 | |
| SCHEMBL10476540 | 0.70 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL22361954 | 0.70 | SLC6A4 (0.42) | ALDH1A1OPRK1LIG1 | |
| SCHEMBL22361952 | 0.70 | SLC6A3 (0.46) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200267977-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3692019-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2020-08-12 | — | — | EP | disclosed |
| CN-111183133-A | Microbicidal picolinamide derivatives | 先正达参股股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019068812-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200267977-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | PRF1, CASP1, FPR1 | CYP2A6 622/4885ALDH1A1 1067/4885TAAR1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.